{"nctId":"NCT00325143","briefTitle":"Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine","startDateStruct":{"date":"2003-12-01"},"conditions":["Haemophilus Influenzae Type b","Diphtheria","Tetanus","Poliomyelitis","Acellular Pertussis"],"count":702,"armGroups":[{"label":"Infanrix Hexa Group","type":"EXPERIMENTAL","interventionNames":["Biological: DTPa-HBV-IPV/Hib","Biological: DTPa-IPV/Hib vaccine"]}],"interventions":[{"name":"DTPa-HBV-IPV/Hib","otherNames":["INFANRIX HEXA™"]},{"name":"DTPa-IPV/Hib vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n* Subjects must have been enrolled in the Rota-028 study.\n* Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.\n* A male or female between, and including, 11 and 17 weeks of age at the time of the first vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n* Subjects should have received two doses of hepatitis B vaccine: at birth and at approximately one month of age.\n\nExclusion criteria\n\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of the vaccine and ending 30 days after.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.\n* A family history of congenital or hereditary immunodeficiency.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures.\n* Acute disease at the time of enrolment.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.","healthyVolunteers":true,"sex":"ALL","minimumAge":"11 Weeks","maximumAge":"17 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Any Solicited Local Symptoms","description":"Assessed solicited local and general symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"301","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"273","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any Solicited General Symptoms","description":"Assessed solicited general symptoms were drowsiness, fever \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"321","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Large Swelling Reactions","description":"A large swelling reaction was defined as swelling with a diameter greater than (\\>) 50 millimeters (mm), noticeable diffuse swelling or noticeable increase of limb circumference.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":108,"n":702},"commonTop":["Irritability","Fever (Axillary) (°C)","Loss of appetite","Pain","Drowsiness"]}}}